83 Results for "

Human PBMC cells

" in MedChemExpress (MCE) Product Catalog:
Products (83)

83 Results for "Human PBMC cells" in MCE Product Catalog:

3
3 Cited Publications
Cat. No.: HY-114170
CAS No.: 1140517-08-3
Purity:  ≥98.0%
Target:  

Proteasome

Research Areas:  

Inflammation/Immunology

ML604440 is a specific and cell-permeable Proteasome β1i (LMP2) subunit inhibitor. ML604440 can be used in experimental colitis, EAE and autoimmune disease research. ML604440 shows synergistic effects and advantageous when combined with LMP7 inhibitor .
loading...
    loading...
1
1 Cited Publications
Cat. No.: HY-150096
CAS No.: 2272904-53-5
Purity:  98.98%
Synonyms: NDI-034858; TAK-279
Target:  

JAK

Research Areas:  

Inflammation/Immunology

Zasocitinib (NDI-034858) is a TYK2 inhibitor, target TYK2 JH2 domain with binding constant Kd of <200 pM .
loading...
    loading...
1
1 Cited Publications
Cat. No.: HY-153220
CAS No.: 2416131-46-7
Purity:  98.67%
Synonyms: NX-2127
Target:  

PROTACs Btk

Research Areas:  

Cancer

Zelebrudomide is an orally active BTK-targeting PROTAC degrader, with DC50 values of 4.5 nM and 31 nM against wild-type BTK and BTK C481S mutant, respectively. Zelebrudomide recruits the cereblon E3 ubiquitin ligase complex to mediate the degradation of BTK. Zelebrudomide also acts as a molecular glue to bind the cereblon E3 ubiquitin ligase complex, mediating the degradation of IKZF1 and IKZF3. Zelebrudomide can be used in the research of B-cell malignancies .
loading...
    loading...
1
1 Cited Publications
Cat. No.: HY-P990876
CAS No.: 2911580-96-4
Synonyms: PF-06480605; RVT-3101

Target:  

TNF Receptor NF-κB IFNAR

Research Areas:  

Inflammation/Immunology

Afimkibart (PF-06480605; RVT-3101) is a fully human monoclonal antibody that selectively inhibits trimeric tumor necrosis factor-like ligand 1A (TL1A). Afimkibart neutralizes active trimeric TL1A, blocks TL1A-induced signaling pathways. Afimkibart inhibits NF-κB activation and IFN-γ production. Afimkibart can be used for the research of inflammatory bowel disease .
loading...
    loading...
1
1 Cited Publications
Cat. No.: HY-117878
CAS No.: 1632125-79-1
Purity:  99.37%
ML345 is a potent and selective inhibitor of insulin-degrading enzyme (IDE) and NLRP3, with an IC50 of 188 nM against IDE. ML345 targets the Cys819 residue of IDE to inhibit IDE. ML345 selectively binds to NLRP3 in a non-covalent manner. ML345 inhibits inflammatory cytokines (IL-1β, IL-6) and exhibits potent anti-inflammatory activity. ML345 exerts a protective effect against miscarriage .
loading...
    loading...
1
1 Cited Publications
Cat. No.: HY-144987
CAS No.: 2597933-17-8
Purity:  98.84%
Target:  

CD38 LAG-3 Tim3 PD-1/PD-L1

Research Areas:  

Inflammation/Immunology Cancer

RBN013209 is an orally active small molecule inhibitor of CD38 with an IC50 of 0.01 to 0.1 μM for human CD38. RBN013209 prevents the conversion of extracellular NAD + to ADPR or cADPR in tumor cells and PBMCs. RBN013209 can be used in the study of tumor. In addition, RBN013209 enables CAR-T cells to maintain the naive state and central memory state, and decreases the expression of cell activation markers and exhaustion-related inhibitory receptors .
loading...
    loading...
1
1 Cited Publications
Cat. No.: HY-162501
CAS No.: 3041134-13-5
Target:  

Piezo Channel

Research Areas:  

Inflammation/Immunology

Yaddle1 is an agonist of the mechano-activated ion channel (Piezo1) with a half-maximal effective concentration (MEC50) of 0.40 μM. Yaddle1 can significantly trigger Ca 2+ inflow in T cells and induce T cell activation response. Yaddle1 can be used in the study of vaccine adjuvants .
loading...
    loading...
1
1 Cited Publications
Cat. No.: HY-158421
CAS No.: 63498-32-8
Purity:  99.95%
MS-L6 is a OXPHOS inhibitor and antimalarial agent. MS-L6 inhibits NADH oxidation and electron transport. MS-L6 induces OXPHOS uncoupling, dissipates mitochondrial membrane potential, increases non-ATP-coupled oxygen consumption, and reduces ATP synthesis. MS-L6 triggers the production of ROS. MS-L6 exhibits anti-amoebic activity. MS-L6 exerts antitumor activity in mouse lymphoma xenograft models. MS-L6 can be used in research related to B-cell lymphoma, T-cell lymphoma, and non-Hodgkin B-cell lymphoma .
loading...
    loading...
1
1 Cited Publications
Cat. No.: HY-K0304

MCE Human CD3+ T Cells Negative Selection Kit is designed for the isolation of CD3+ T cells from human peripheral blood mononuclear cells (PBMC).

loading...
    loading...
1
1 Cited Publications
Cat. No.: HY-K0351

MCE Human CD8+ T Cells Negative Selection Kit is designed to isolate CD8+ T cells from human peripheral blood mononuclear cells (PBMCs).

loading...
    loading...
1
1 Cited Publications
Cat. No.: HY-K0352

MCE Human CD4+ T Cells Negative Selection Kit is designed to isolate CD4+ T cells from human peripheral blood mononuclear cells (PBMCs).

loading...
    loading...
Cat. No.: HY-P990774
CAS No.: 2768386-15-6
Synonyms: ASP-7266; TRAB-1; UPB-101

Target:  

Interleukin Related

Research Areas:  

Inflammation/Immunology

Verekitug (ASP-7266; TRAB-1; UPB-101) is a human monoclonal antibody targeting the thymic stromal lymphopoietin receptor (TSLPR), with a mean half-life of approximately 20 days. At doses of Verekitug ≥100 mg, complete and sustained TSLPR-specific occupancy is achieved, and the antibody does not bind to IL-7Rα. By inhibiting TSLP-driven inflammatory responses, Verekitug blocks TSLP-induced cell proliferation and TARC expression, while reducing fractional exhaled NO levels, blood eosinophil counts, and levels of IL-5 and IgE. Verekitug significantly improves scores for nasal polyps, nasal congestion and olfactory dysfunction, with favorable safety and good tolerability; potential adverse reactions include headache, upper respiratory tract infection, sinusitis and nasopharyngitis. Verekitug is used in relevant studies on asthma, chronic rhinosinusitis with nasal polyps and chronic obstructive pulmonary disease .
loading...
    loading...
Cat. No.: HY-156438
CAS No.: 2272917-13-0
Purity:  99.65%
Synonyms: NT-0796
Ruvonoflast (NT-0796) is an orally active, selective and CNS-penetrant NLRP3 inflammasome inhibitor. Ruvonoflast inhibits IL-1β release in human PBMC cells with an IC50 value of 0.32 nM. Ruvonoflast is an isopropyl ester that undergoes intracellular conversion to Ruvonoflast, the carboxylic acid active species. Ruvonoflast reverses high fat diet-induced obesity, systemic inflammation and astrogliosis in the diet-induced obesity mouse model. Ruvonoflast is promising for research of neurodegenerative disorders, including Alzheimer’s disease, Parkinson’s disease, multiple sclerosis, and amyotrophic lateral sclerosis .
loading...
    loading...
Cat. No.: HY-164827
CAS No.: 2862772-71-0
Target:  

Molecular Glues CDK

Research Areas:  

Cancer

CDK2 degrader 3 is a selective CDK2 molecular glue-like degrader. CDK2 degrader 3 induces G1 cell cycle arrest in CCNE1-amplified cancer cells. CDK2 degrader 3 is applicable to breast cancer-related research .
loading...
    loading...
Cat. No.: HY-132248
CAS No.: 191732-70-4
Purity:  99.62%
Synonyms: Lenalidomide 5'-amine
Research Areas:  

Inflammation/Immunology

C5 Lenalidomide is a 5-amino-substituted Thalidomide (HY-14658) analog. C5 Lenalidomide inhibits LPS (HY-D1056)-stimulated TNF-α production .
loading...
    loading...
Cat. No.: HY-P11072
CAS No.: 1601299-92-6
IRF5-CPP5 is a cytosolic peptide that selectively targeting human IRF5 wirh a Kd of 0.53 μM. IRF5-CPP5 disrupts IRF5 homodimerization and inhibits its nuclear translocation without altering IRF5 phosphorylation levels. IRF5-CPP5 inhibits proinflammatory cytokine (IL-6, IL-1β, TNF-α) production. IRF5-CPP5 can be used for the research of systemic lupus erythematosus .
loading...
    loading...
Cat. No.: HY-P991440

Target:  

TNF Receptor

Research Areas:  

Inflammation/Immunology

AMG-966 is a human bispecific antibody (bsAb) targeting TNFSF15/TL1A & TNFα. AMG 966 restores the ability of the aglycosylated Fc domain to bind FcγRIa and FcγRIIa, leading to the formation of anti-drug antibodies (ADA). AMG 966 can be used in research on Crohn's disease and ulcerative colitis. Recommended isotype control: Human IgG1 kappa, Isotype Control (HY-P99001) .
loading...
    loading...
Cat. No.: HY-138568
CAS No.: 2739844-34-7
Purity:  98.61%
Target:  

MAP4K

Research Areas:  

Inflammation/Immunology

HPK1-IN-3 is a potent and selective ATP-competitive hematopoietic progenitor kinase 1 (HPK1; MAP4K1) inhibitor with an IC50 of 0.25 nM. HPK1-IN-3 has IL-2 cellular potency with an EC50 of 108 nM in human peripheral blood mononuclear cells (PBMCs) .
loading...
    loading...
Cat. No.: HY-177338
CAS No.: 2361424-97-5
STING agonist-45 is a selective STING agonist (EC50 = 0.28 μM). STING agonist-45 activates the innate immune response through the cGAS-STING pathway, upregulating key markers such as p-TBK1 and IRF3. STING agonist-45 exhibits robust STING activation in human peripheral blood mononuclear cells (PBMCs), inducing the production of type I interferons (such as IFN-β) and downstream cytokines (such as TNF-α and IL-6). STING agonist-45 enhances anti-tumor immunity, inhibits tumor growth, and increases CD8 + T cell infiltration in mouse models. STING agonist-45 is promising for the study of STING-related diseases .
loading...
    loading...
Cat. No.: HY-14837
CAS No.: 201349-37-3
Synonyms: Enisamium iodide
Research Areas:  

Infection

Amizon is an orally effective antiviral and anti-inflammatory agent. Amizon inhibits influenza virus replication and restricts viral RNA synthesis. Amizon reduces the mRNA expression of COX-1, COX-2, NF-κB, TGF1β, IL-1 and IL-6, and stimulates the secretion and mRNA expression of IL-10. Amizon inhibits the oxidative activity of macrophages and possesses antioxidant and free radical-scavenging activities. Amizon is applicable to research related to influenza and acute respiratory viral infections .
loading...
    loading...